Ronan Roussel

List of Publications by Year
in descending order

141 papers	6,887 citations	117571 34 h-index	71651 76 g-index
149 all docs	149 docs citations	149 times ranked	14616 citing authors

#	Article	IF	Citations
1	History of bariatric surgery and COVIDâ€19 outcomes in patients with type 2 diabetes: Results from the CORONADO study. Obesity, 2022, 30, 599-605.	1.5	7
2	Association Between the ACE Insertion/Deletion Polymorphism and Risk of Lower-Limb Amputation in Patients With Long-Standing Type 1 Diabetes. Diabetes Care, 2022, 45, 407-415.	4.3	3
3	Hypertriglyceridemia in the MESA Study. JAMA Cardiology, 2022, , .	3.0	0
4	Epigenetic changes associated with hyperglycaemia exposure in the longitudinal D.E.S.I.R. cohort. Diabetes and Metabolism, 2022, 48, 101347.	1.4	0
5	Differential prognostic burden of cardiovascular disease and lower-limb amputation on the risk of all-cause death in people with long-standing type 1 diabetes. Cardiovascular Diabetology, 2022, 21, 71.	2.7	2
6	Reduced Rate of Acute Diabetes Events with Flash Glucose Monitoring Is Sustained for 2 Years After Initiation: Extended Outcomes from the RELIEF Study. Diabetes Technology and Therapeutics, 2022, 24, 611-618.	2.4	13
7	Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19. Diabetes and Metabolism, 2021, 47, 101216.	1.4	65
8	Plasma concentrations of lipoproteins and risk of lower-limb peripheral artery disease in people with type 2 diabetes: the SURDIAGENE study. Diabetologia, 2021, 64, 668-680.	2.9	12
9	Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study. Diabetologia, 2021, 64, 778-794.	2.9	120
10	Use of dipeptidyl peptidaseâ€4 inhibitors and prognosis of <scp>COVID</scp>â€19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the <scp>CORONADO</scp> study. Diabetes, Obesity and Metabolism, 2021, 23, 1162-1172.	2.2	33
11	COVID-19 symptoms masking inaugural ketoacidosis of type 1 diabetes. Diabetes and Metabolism, 2021, 47, 101162.	1.4	22
12	ACE I/D Polymorphism, Plasma ACE Levels, and Long-term Kidney Outcomes or All-Cause Death in Patients With Type 1 Diabetes. Diabetes Care, 2021, 44, 1377-1384.	4.3	6
13	Important Drop in Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The RELIEF Study. Diabetes Care, 2021, 44, 1368-1376.	4.3	59
14	SGLT2 inhibitors and lower limb complications: the diuretic-induced hypovolemia hypothesis. Cardiovascular Diabetology, 2021, 20, 107.	2.7	13
15	Diabetes Increases Severe COVID-19 Outcomes Primarily in Younger Adults. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3364-e3368.	1.8	16
16	Is the Consensual Threshold for Defining High Glucose Variability Implementable in Clinical Practice?. Diabetes Care, 2021, 44, 1722-1725.	4.3	10
17	Association of diabetes and outcomes in patients with COVID-19: Propensity score-matched analyses from a French retrospective cohort. Diabetes and Metabolism, 2021, 47, 101222.	1.4	15
18	The COVID-19 lockdown as an opportunity to change lifestyle and body weight in people with overweight/obesity and diabetes: Results from the national French COVIDIAB cohort. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2605-2611.	1.1	15

#	Article	IF	Citations
19	Exposure to persistent organic pollutants and the risk of type 2 diabetes: a case-cohort study. Diabetes and Metabolism, 2021, 47, 101234.	1.4	19
20	Reliability and Safety of Bedside Blind Bone Biopsy Performed by a Diabetologist for the Diagnosis and Treatment of Diabetic Foot Osteomyelitis. Diabetes Care, 2021, 44, 2480-2486.	4.3	5
21	Identification of Key Regions Mediating Human Melatonin Type 1 Receptor Functional Selectivity Revealed by Natural Variants. ACS Pharmacology and Translational Science, 2021, 4, 1614-1627.	2.5	4
22	Stay-at-Home Orders During the COVID-19 Pandemic, an Opportunity to Improve Glucose Control Through Behavioral Changes in Type 1 Diabetes. Diabetes Care, 2021, 44, 839-843.	4.3	36
23	Une vision de lâ€™organisation moderne dâ€™un service hospitalier de diabÃ©tologie. Medecine Des Maladies Metaboliques, 2021, 15, 585-590.	0.1	1
24	Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: the SFDT1 study. Diabetes and Metabolism, 2021, 48, 101306.	1.4	0
25	Head-to-head comparison of the diagnostic performances of Rubidium-PET and SPECT with CZT camera for the detection of myocardial ischemia in a population of women and overweight individuals. Journal of Nuclear Cardiology, 2020, 27, 755-768.	1.4	14
26	Dairy consumption is associated with lower plasma dihydroceramides in women from the D.E.S.I.R. cohort. Diabetes and Metabolism, 2020, 46, 144-149.	1.4	3
27	Disagreement between capillary blood glucose and flash glucose monitoring sensor can lead to inadequate treatment adjustments during pregnancy. Diabetes and Metabolism, 2020, 46, 158-163.	1.4	14
28	The expression of genes in top obesity-associated loci is enriched in insula and substantia nigra brain regions involved in addiction and reward. International Journal of Obesity, 2020, 44, 539-543.	1.6	38
29	Real-world outcomes of treatment with insulin glargine 300â€‰U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus. Current Medical Research and Opinion, 2020, 36, 571-581.	0.9	12
30	SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes. Diabetes and Metabolism, 2020, 46, 203-209.	1.4	13
31	Pathogenic variants in actionable MODY genes are associated with type 2 diabetes. Nature Metabolism, 2020, 2, 1126-1134.	5.1	43
32	Adipocyte Reprogramming by the Transcriptional Coregulator GPS2 Impacts Beta Cell Insulin Secretion. Cell Reports, 2020, 32, 108141.	2.9	9
33	Type 1 Diabetes in People Hospitalized for COVID-19: New Insights From the CORONADO Study. Diabetes Care, 2020, 43, e174-e177.	4.3	35
34	Relationship Between Diabetic Retinopathy Stages and Risk of Major Lower-Extremity Arterial Disease in Patients With Type 2 Diabetes. Diabetes Care, 2020, 43, 2751-2759.	4.3	10
35	Blood glucose levels and COVID-19. Reply to Sardu C, Dâ€™Onofrio N, Balestrieri ML et al [letter] and Lepper PM, Bals R, JÃ¼ni P et al [letter]. Diabetologia, 2020, 63, 2491-2494.	2.9	4
36	Comparison of a new versus standard removable offloading device in patients with neuropathic diabetic foot ulcers: a French national, multicentre, open-label randomized, controlled trial. BMJ Open Diabetes Research and Care, 2020, 8, e000954.	1.2	3

#	Article	IF	Citations
37	Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia, 2020, 63, 1500-1515.	2.9	638
38	Chronic Kidney Disease, Diabetes, and Risk of Mortality After Acute Myocardial Infarction: Insight From the FAST-MI Program. Diabetes Care, 2020, 43, e43-e44.	4.3	10
39	Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters. Diabetes Care, 2020, 43, 1695-1703.	4.3	147
40	Persistence with Basal Insulin and Frequency of Hypoglycemia Requiring Hospitalization in Patients with Type 2 Diabetes. Diabetes Therapy, 2020, 11, 1861-1872.	1.2	3
41	Leukocyte Telomere Length, DNA Oxidation, and Risk of Lower-Extremity Amputation in Patients With Long-standing Type 1 Diabetes. Diabetes Care, 2020, 43, 828-834.	4.3	11
42	Relationship between renal capacity to reabsorb glucose and renal status in patients with diabetes. Diabetes and Metabolism, 2020, 46, 488-495.	1.4	1
43	Insulin glargine 300â€‰U/<scp>mL</scp> and insulin degludec: A review of the current evidence comparing these two secondâ€generation basal insulin analogues. Diabetes/Metabolism Research and Reviews, 2020, 36, e3329.	1.7	12
44	Plasma Trimethylamine N-Oxide and Risk of Cardiovascular Events in Patients With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2371-2380.	1.8	35
45	Plasma Apelin and Risk of Type 2 Diabetes in a Cohort From the Community. Diabetes Care, 2020, 43, e15-e16.	4.3	12
46	Loss-of-function mutations in MRAP2 are pathogenic in hyperphagic obesity with hyperglycemia and hypertension. Nature Medicine, 2019, 25, 1733-1738.	15.2	54
47	Glycosuria amount in response to hyperglycaemia and risk for diabetic kidney disease and related events in Type 1 diabetic patients. Nephrology Dialysis Transplantation, 2019, 34, 1731-1738.	0.4	9
48	New roles for prokineticin 2 in feeding behavior, insulin resistance and type 2 diabetes: Studies in mice and humans. Molecular Metabolism, 2019, 29, 182-196.	3.0	15
49	Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 Diabetes. Diabetes Care, 2019, 42, 2290-2297.	4.3	15
50	Severe Chronic Kidney Disease Is Associated with a Lower Efficiency of Bariatric Surgery. Obesity Surgery, 2019, 29, 1514-1520.	1.1	16
51	Letter by Potier and Roussel Regarding Article, â€œAre We Ready to Bell the Cat? A Call for Cardiologists to Embrace Glucose-Lowering Therapies Proven to Improve Cardiovascular Outcomesâ€. Circulation, 2019, 139, 303-304.	1.6	0
52	Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study. Diabetes Therapy, 2019, 10, 617-633.	1.2	50
53	Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use. Diabetologia, 2019, 62, 939-947.	2.9	36
54	Doubleâ€blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidaseâ€4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSITâ€‐Study. Diabetes, Obesity and Metabolism, 2019, 21, 781-790.	2.2	19

#	Article	IF	Citations
55	Effects of hydration on plasma copeptin, glycemia and gluco-regulatory hormones: a water intervention in humans. European Journal of Nutrition, 2019, 58, 315-324.	1.8	43
56	No prognostic role of a GWAS-derived genetic risk score in renal outcomes for patients from French cohorts with type 1 and type 2 diabetes. Diabetes and Metabolism, 2019, 45, 494-497.	1.4	5
57	Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300 U/mL vs glargine 100 U/mL in T2DM. Diabetes and Metabolism, 2018, 44, 402-409.	1.4	33
58	Agonistes du rÃ©cepteur du GLP-1 : puissance ou transcendance ? Des outils pour contrÃ´ler glycÃ©mie et pression artÃ©rielle. Medecine Des Maladies Metaboliques, 2018, 12, 31-35.	0.1	1
59	Nonâ€severe hypoglycaemia is associated with weight gain in patients with type 1 diabetes: Results from the Diabetes Control and Complication Trial. Diabetes, Obesity and Metabolism, 2018, 20, 1289-1292.	2.2	15
60	Associations of fats and carbohydrates with cardiovascular disease and mortalityâ€"PURE and simple?. Lancet, The, 2018, 391, 1680.	6.3	1
61	Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: <scp>A</scp> perspective on glucoseâ€lowering interventions. Diabetes, Obesity and Metabolism, 2018, 20, 238-244.	2.2	58
62	Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twiceâ€daily basal insulin to onceâ€daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2) Tj ETQq0 0 0 rgBT /Overlock 1	2.2	
63	Better glycaemic control and less hypoglycaemia with insulin glargine 300 <scp>U/mL</scp> vs glargine 100 <scp>U/mL</scp>: 1â€year patientâ€level metaâ€analysis of the <scp>EDITION</scp> clinical studies in people with type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 541-548.	2.2	69
64	Plasma concentrations of 8-hydroxy-2â€²-deoxyguanosine and risk of kidney disease and death in individuals with type 1 diabetes. Diabetologia, 2018, 61, 977-984.	2.9	28
65	Morning administration of 0.4 U/kg/day insulin glargine 300 U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 diabetes. Diabetes and Metabolism, 2018, 44, 15-21.	1.4	81
66	Lower extremity arterial disease in patients with diabetes: a contemporary narrative review. Cardiovascular Diabetology, 2018, 17, 138.	2.7	104
67	Le traitement du diabÃ¨te de type 2 en France est dynamique plutÃ´t quâ€™inerte : analyse des prescriptions de 847 122 patients. Medecine Des Maladies Metaboliques, 2018, 12, 346-352.	0.1	4
68	GPS2 Deficiency Triggers Maladaptive White Adipose Tissue Expansion in Obesity via HIF1A Activation. Cell Reports, 2018, 24, 2957-2971.e6.	2.9	48
69	Clinical outcomes in realâ€world patients with type 2 diabetes switching from firstâ€to secondâ€generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study. Diabetes, Obesity and Metabolism, 2018, 20, 2148-2158.	2.2	59
70	Impaired Aryl Hydrocarbon Receptor Ligand Production by the Gut Microbiota Is a Key Factor in Metabolic Syndrome. Cell Metabolism, 2018, 28, 737-749.e4.	7.2	356
71	Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes. Cardiovascular Diabetology, 2018, 17, 110.	2.7	35
72	Prognostic Values of Inflammatory and Redox Status Biomarkers on the Risk of Major Lower-Extremity Artery Disease in Individuals With Type 2 Diabetes. Diabetes Care, 2018, 41, 2162-2169.	4.3	14

#	Article	IF	Citations
73	Bariatric surgery and chronic kidney disease: much hope, but proof is still awaited. International Journal of Obesity, 2018, 42, 1532-1533.	1.6	4
74	Relationship between cardiac microvascular dysfunction measured with 82Rubidium-PET and albuminuria in patients with diabetes mellitus. Cardiovascular Diabetology, 2018, 17, 11.	2.7	28
75	More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial. Diabetes Care, 2018, 41, 2147-2154.	4.3	159
76	A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study. Diabetes Care, 2018, 41, 1672-1680.	4.3	44
77	Plasma proproteinâ€convertaseâ€subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 943-953.	2.2	17
78	Plasma copeptin and chronic kidney disease risk in 3 European cohorts from the general population. JCI Insight, 2018, 3, .	2.3	32
79	Sex hormone levels are not associated with progression of renal disease in male patients with T2DM. Diabetes and Metabolism, 2017, 43, 140-145.	1.4	5
80	T-cadherin gene variants are associated with type 2 diabetes and the Fatty Liver Index in the French population. Diabetes and Metabolism, 2017, 43, 33-39.	1.4	14
81	Predicting severe hypoglycaemia with self-monitoring of blood glucose in type 1 diabetes. Diabetes and Metabolism, 2017, 43, 392-394.	1.4	2
82	Vasopressin and diabetic nephropathy. Current Opinion in Nephrology and Hypertension, 2017, 26, 311-318.	1.0	18
83	Antagonism of vasopressin V2 receptor improves albuminuria at the early stage of diabetic nephropathy in a mouse model of type 2 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 929-932.	1.2	16
84	T-cadherin gene variants are associated with nephropathy in subjects with type 1 diabetes. Nephrology Dialysis Transplantation, 2017, 32, 1987-1993.	0.4	2
85	Urinary lysophopholipids are increased in diabetic patients with nephropathy. Journal of Diabetes and Its Complications, 2017, 31, 1103-1108.	1.2	24
86	Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. Heart, 2017, 103, 1339-1346.	1.2	38
87	Association of Circulating Biomarkers (Adrenomedullin, TNFR1, and NT-proBNP) With Renal Function Decline in Patients With Type 2 Diabetes: A French Prospective Cohort. Diabetes Care, 2017, 40, 367-374.	4.3	43
88	The vasopressin system: new insights for patients with kidney diseases. Journal of Internal Medicine, 2017, 282, 310-321.	2.7	17
89	Short-term effect of severe hypoglycaemia on glycaemic control in the Diabetes Control and Complications Trial. Diabetes and Metabolism, 2017, 43, 187-190.	1.4	1
90	Urinary Sodium Concentration Is an Independent Predictor of All-Cause and Cardiovascular Mortality in a Type 2 Diabetes Cohort Population. Journal of Diabetes Research, 2017, 2017, 1-10.	1.0	12

#	Article	IF	Citations
91	Association of impaired renal function with venous thrombosis: A genetic risk score approach. Thrombosis Research, 2017, 158, 102-107.	0.8	2
92	A Fully Automated Web-Based Program Improves Lifestyle Habits and HbA1c in Patients With Type 2 Diabetes and Abdominal Obesity: Randomized Trial of Patient E-Coaching Nutritional Support (The) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50		
93	Gene Polymorphisms of FABP2, ADIPOQ and ANP and Risk of Hypertriglyceridemia and Metabolic Syndrome in Afro-Caribbeans. PLoS ONE, 2016, 11, e0163421.	1.1	10
94	Metformin and contrast-induced acute kidney injury in diabetic patients treated with primary percutaneous coronary intervention for ST segment elevation myocardial infarction: Amulticenter study. International Journal of Cardiology, 2016, 220, 137-142.	0.8	24
95	Dynamic Changes in Renal Function Are Associated With Major Cardiovascular Events in Patients With Type 2 Diabetes. Diabetes Care, 2016, 39, 1259-1266.	4.3	38
96	Interaction between GPR120 p.R270H loss-of-function variant and dietary fat intake on incident type 2 diabetes risk in the D.E.S.I.R. study. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 931-936.	1.1	9
97	Plasma Copeptin, AVP Gene Variants, and Incidence of Type 2 Diabetes in a Cohort From the Community. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2432-2439.	1.8	58
98	Plasma Copeptin, Kidney Outcomes, Ischemic Heart Disease, and All-Cause Mortality in People With Long-standing Type 1 Diabetes. Diabetes Care, 2016, 39, 2288-2295.	4.3	51
99	ANGPTL2 is associated with an increased risk of cardiovascular events and death in diabetic patients. Diabetologia, 2016, 59, 2321-2330.	2.9	30
100	Impact of statistical models on the prediction of type 2 diabetes using non-targeted metabolomics profiling. Molecular Metabolism, 2016, 5, 918-925.	3.0	18
101	Longitudinal association of antidepressant medication use with metabolic syndrome: Results of a 9-year follow-up of the D.E.S.I.R. cohort study. Psychoneuroendocrinology, 2016, 74, 34-45.	1.3	10
102	Randomized Trials to Evaluate Cardiovascular Safety of Antihyperglycemic Medications. Circulation, 2016, 134, 571-573.	1.6	16
103	Improvement of skin wound healing in diabetic mice by kinin B2 receptor blockade. Clinical Science, 2016, 130, 45-56.	1.8	19
104	Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims Study. Diabetes Therapy, 2016, 7, 537-549.	1.2	28
105	The evaluation of offâ€loading using a new removable oRTHOsis in DIABetic foot (ORTHODIAB) randomized controlled trial: study design and rationale. Journal of Foot and Ankle Research, 2016, 9, 34.	0.7	8
106	Beta-cell function is associated with carotid intima-media thickness independently of insulin resistance in healthy individuals. Journal of Hypertension, 2016, 34, 685-691.	0.3	15
107	Lifestyle intervention enhances high-density lipoprotein function among patients with metabolic syndrome only at normal low-density lipoprotein cholesterol plasma levels. Journal of Clinical Lipidology, 2016, 10, 1172-1181.	0.6	13
108	Lower-extremity amputation as a marker for renal and cardiovascular events and mortality in patients with long standing type 1 diabetes. Cardiovascular Diabetology, 2016, 15, 5.	2.7	20

#	Article	IF	Citations
109	Glutathione peroxidase-1 gene (GPX1) variants, oxidative stress and risk of kidney complications in people with type 1 diabetes. Metabolism: Clinical and Experimental, 2016, 65, 12-19.	1.5	37
110	Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics, 2016, 19, 131-144.	1.0	16
111	Patientâ€level metaâ€analysis of the <scp>EDITION</scp> 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes, Obesity and Metabolism, 2015, 17, 859-867.	2.2	207
112	Contribution of the low-frequency, loss-of-function p.R270H mutation inFFAR4(GPR120) to increased fasting plasma glucose levels. Journal of Medical Genetics, 2015, 52, 595-598.	1.5	29
113	Plasma Copeptin and Decline in Renal Function in a Cohort from the Community: The Prospective D.E.S.I.R. Study. American Journal of Nephrology, 2015, 42, 107-114.	1.4	43
114	Plasma extracellular superoxide dismutase concentration, allelic variations in the SOD3 gene and risk of myocardial infarction and all-cause mortality in people with type 1 and type 2 diabetes. Cardiovascular Diabetology, 2015, 14, 845.	2.7	47
115	Cardiovascular risk in relation to body mass index and use of evidence-based preventive medications in patients with or at risk of atherothrombosis. European Heart Journal, 2015, 36, 2716-2728.	1.0	48
116	Allelic variations in the CYBA gene of NADPH oxidase and risk of kidney complications in patients with type 1 diabetes. Free Radical Biology and Medicine, 2015, 86, 16-24.	1.3	14
117	ABCG8 polymorphisms and renal disease in type 2 diabetic patients. Metabolism: Clinical and Experimental, 2015, 64, 713-719.	1.5	11
118	Plasma Adrenomedullin and Allelic Variation in the ADM Gene and Kidney Disease in People With Type 2 Diabetes. Diabetes, 2015, 64, 3262-3272.	0.3	12
119	Protein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and urea. American Journal of Physiology - Renal Physiology, 2015, 309, F2-F23.	1.3	88
120	Antidepressant medication use and trajectories of fasting plasma glucose, glycated haemoglobin, Î²-cell function and insulin sensitivity: a 9-year longitudinal study of the D.E.S.I.R. cohort. International Journal of Epidemiology, 2015, 44, 1927-1940.	0.9	14
121	Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease. Advances in Therapy, 2015, 32, 1029-1064.	1.3	30
122	Kinin Receptor Agonism Restores Hindlimb Postischemic Neovascularization Capacity in Diabetic Mice. Journal of Pharmacology and Experimental Therapeutics, 2015, 352, 218-226.	1.3	19
123	Use of Fibrates Monotherapy in People with Diabetes and High Cardiovascular Risk in Primary Care: A French Nationwide Cohort Study Based on National Administrative Databases. PLoS ONE, 2015, 10, e0137733.	1.1	12
124	Comparison Between Copeptin and Vasopressin in a Population From the Community and in People With Chronic Kidney Disease. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4656-4663.	1.8	110
125	Association of Serum Concentration of TNFR1 With All-Cause Mortality in Patients With Type 2 Diabetes and Chronic Kidney Disease: Follow-up of the SURDIAGENE Cohort. Diabetes Care, 2014, 37, 1425-1431.	4.3	65
126	Defining the role of common variation in the genomic and biological architecture of adult human height. Nature Genetics, 2014, 46, 1173-1186.	9.4	1,818

#	Article	IF	Citations
127	Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials. Journal of Diabetes and Its Complications, 2014, 28, 40-44.	1.2	28
128	Manganese Superoxide Dismutase (SOD2) Polymorphisms, Plasma Advanced Oxidation Protein Products (AOPP) Concentration and Risk of Kidney Complications in Subjects with Type 1 Diabetes. PLoS ONE, 2014, 9, e96916.	1.1	31
129	Catalase activity, allelic variations in the catalase gene and risk of kidney complications in patients with type 1 diabetes. Diabetologia, 2013, 56, 2733-2742.	2.9	14
130	Plasma Copeptin and Renal Outcomes in Patients With Type 2 Diabetes and Albuminuria. Diabetes Care, 2013, 36, 3639-3645.	4.3	73
131	FRI0546â€…Pituitary-adrenal function after prolonged glucocorticoid therapy in systemic disorders. Annals of the Rheumatic Diseases, 2013, 72, A559.3-A560.	0.5	0
132	ContrÃ1e intensif de la glycÃ©mie: moins dâ€™infarctus du myocarde. Diabetologia Notes De Lecture, 2010, 2, 15-16.	0.0	0
133	Metformin Use and Mortality Among Patients With Diabetes and Atherothrombosis<alt-title>Metformin Use With Diabetes and Atherothrombosis</alt-title>. Archives of Internal Medicine, 2010, 170, 1892.	4.3	319
134	Hypoglycaemia? Not guilty! Decreased HbA1c? Not guilty!. Diabetes and Metabolism, 2010, 36, 86-87.	1.4	0
135	Le salsalate, un dÃ©rivÃ© de lâ€™aspirine, pourrait Ãªtre un anti-diabÃ©tique, en agissant plutÃ´t sur lâ€™insulinosÃ©crÃ©tion que lâ€™insulinosensibilitÃ©. Diabetologia Notes De Lecture, 2009, 1, 1-2.	0.0	1
136	Mesure de lâ€™accumulation cutanÃ©e des produits avancÃ©s de la glycation: un progrÃ¨s pour la prÃ©diction du risque cardiovasculaire ?. Diabetologia Notes De Lecture, 2009, 1, 31-32.	0.0	0
137	Le diabÃ¨te et lâ€™obÃ©sitÃ©, rÃ©ellement des maladies hÃ©ritÃ©es dâ€™un passÃ© de chasseurs-cueilleurs ?. Diabetologia Notes De Lecture, 2009, 1, 35-36.	0.0	5
138	La micro-angiopathie: plus de prÃ©vention possible aprÃ¨s quelques annÃ©es de diabÃ¨te de type 2 ?. Diabetologia Notes De Lecture, 2009, 1, 61-62.	0.0	0
139	Prognostic Value of the Insertion/Deletion Polymorphism of the ACE Gene in Type 2 Diabetic Subjects. Diabetes Care, 2008, 31, 1847-1852.	4.3	66
140	Modulation of the Renal Response to ACE Inhibition by ACE Insertion/Deletion Polymorphism During Hyperglycemia in Normotensive, Normoalbuminuric Type 1 Diabetic Patients. Diabetes, 2005, 54, 2961-2967.	0.3	21
141	Different Patterns of Insulin Resistance in Relatives of Type 1 Diabetic Patients With Retinopathy or Nephropathy: The Genesis France-Belgium Study. Diabetes Care, 2004, 27, 2661-2668.	4.3	55